Duke researchers are developing a new class of non‑opioid painkillers that act inside nerve cells rather than on opioid receptors, aiming to relieve pain without causing addiction. Early studies link chronic nerve pain to mitochondrial dysfunction, and restoring mitochondrial health may help repair nerves at the source. These treatments are still in preclinical development; if results remain promising, human clinical trials could follow.
Duke Researchers Develop Non‑Opioid Painkillers That Target Nerve Cells and Aim To Prevent Addiction
Duke researchers develop new class of non-opioid painkiller to combat addiction
More than 50 million adults in the United States live with chronic pain, and for many, finding effective relief still carries serious risks. Researchers at Duke University are developing a new class of non‑opioid painkillers designed to ease pain without producing the dependence associated with opioids.
Personal Toll and the Need for Alternatives
A car crash more than 25 years ago left Malia Baird with unrelenting, burning pain. "I have pain 24 hours every day and will for the rest of my life," Baird said. "Terrible burning pain. Like if you ever are standing too close to a campfire and you have to back off, it was as though I was standing in a fire." Her story illustrates the scale of the problem: the CDC estimates about one in five U.S. adults live with chronic pain, and many turn to opioids for relief.
Rethinking How Pain Is Treated
Traditional opioid drugs act on well‑known pathways that relieve pain but also create high addiction risk. At Duke, scientists are exploring compounds that work differently — targeting processes inside nerve cells rather than opioid receptors. Early laboratory findings suggest these experimental compounds may both reduce pain and lower addiction potential.
Researchers describe one compound that appears to both inhibit pain and reduce the likelihood of addiction — a goal long considered out of reach.
Mitochondria, Nerve Health and Chronic Pain
New research links chronic nerve pain to mitochondrial dysfunction. Mitochondria are the energy producers inside cells; when they malfunction, nerves can become more sensitive and pain can persist or worsen. Duke researchers believe restoring mitochondrial health could help damaged nerves repair themselves and address pain at the source rather than simply masking symptoms.
Where the Research Stands
These candidate drugs remain in the preclinical stage. Scientists emphasize that laboratory results must be replicated and carefully evaluated for safety and effectiveness before any human use. If continued testing is promising, human clinical trials could follow.
Context and caution: Misuse rates among people with chronic pain have been reported as high as 29 percent, and the opioid crisis continues to exact a heavy toll; experts estimate opioid‑related deaths number in the tens of thousands annually. While the Duke findings are encouraging, more research is required to confirm benefits and potential side effects in people.
Future of Pain Care
Researchers and clinicians expect the future of pain treatment will likely combine multiple approaches — new non‑opioid medicines, medical technology, and non‑drug therapies — to deliver effective relief while minimizing the risk of dependence and overdose.
Help us improve.
